South Korea’s Ministry of Food and Drug Safety announced plans to significantly increase the application fees for biosimilar drug approvals starting in 2026, while simultaneously shortening review timelines. This regulatory shift aims to accelerate market access and encourage biosimilar development despite higher upfront costs for developers. The balance of higher fees and shortened reviews is designed to streamline biosimilar availability in one of Asia’s fast-growing pharmaceutical markets.